• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Retraction: Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer.

出版信息

Cancer Res. 2018 Jun 15;78(12):3397. doi: 10.1158/0008-5472.CAN-18-1182.

DOI:10.1158/0008-5472.CAN-18-1182
PMID:29907682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6093285/
Abstract
摘要

相似文献

1
Retraction: Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer.撤稿声明：尿激酶型纤溶酶原激活剂的去甲基化相关激活参与前列腺癌进展
Cancer Res. 2018 Jun 15;78(12):3397. doi: 10.1158/0008-5472.CAN-18-1182.
2
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.尿激酶型纤溶酶原激活剂的去甲基化相关激活参与前列腺癌进展。
Cancer Res. 2007 Feb 1;67(3):930-9. doi: 10.1158/0008-5472.CAN-06-2892.
3
Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.前列腺癌患者血清中尿激酶型纤溶酶原激活物受体和表皮生长因子受体增加。
J Urol. 2009 Mar;181(3):1393-400. doi: 10.1016/j.juro.2008.10.147. Epub 2009 Jan 20.
4
Retraction: Small Interfering RNA-Directed Reversal of Urokinase Plasminogen Activator Demethylation Inhibits Prostate Tumor Growth and Metastasis.撤回声明：小干扰RNA介导的尿激酶型纤溶酶原激活剂去甲基化逆转抑制前列腺肿瘤生长和转移
Cancer Res. 2018 Jun 15;78(12):3398. doi: 10.1158/0008-5472.CAN-18-1183.
5
Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.阿司匹林通过靶向基质金属蛋白酶-9和尿激酶型纤溶酶原激活剂抑制IKK-β介导的前列腺癌细胞侵袭。
Cell Physiol Biochem. 2017;41(4):1313-1324. doi: 10.1159/000464434. Epub 2017 Mar 8.
6
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.尿激酶、尿激酶受体和纤溶酶原激活物抑制剂-1的联合过表达与乳腺癌进展相关：正常、良性和恶性乳腺组织的免疫组织化学比较
Cancer. 1996 Mar 15;77(6):1079-88. doi: 10.1002/(sici)1097-0142(19960315)77:6<1079::aid-cncr12>3.0.co;2-z.
7
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.缺氧和复氧对人头颈部肿瘤细胞中尿激酶型纤溶酶原激活物、其抑制剂1型纤溶酶原激活物抑制剂及尿激酶型纤溶酶原激活物受体表达水平的影响。
Oncol Rep. 2007 May;17(5):1259-68.
8
Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.去势对大鼠前列腺腹叶纤溶酶原激活物活性及1型纤溶酶原激活物抑制剂的影响。
Prostate. 1996 Apr;28(4):239-50. doi: 10.1002/(SICI)1097-0045(199604)28:4<239::AID-PROS5>3.0.CO;2-8.
9
Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs.健康犬泌尿道中尿激酶型纤溶酶原激活物样蛋白和尿激酶型纤溶酶原激活物受体样蛋白的免疫组织化学染色
Am J Vet Res. 2006 Sep;67(9):1628-34. doi: 10.2460/ajvr.67.9.1628.
10
The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.尿激酶型纤溶酶原激活剂含量与浅表性膀胱癌肿瘤复发情况
J Urol. 1994 Jan;151(1):16-9; discussion 19-20. doi: 10.1016/s0022-5347(17)34861-9.

本文引用的文献

1
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.尿激酶型纤溶酶原激活剂的去甲基化相关激活参与前列腺癌进展。
Cancer Res. 2007 Feb 1;67(3):930-9. doi: 10.1158/0008-5472.CAN-06-2892.